Lung cancer is the leading cause of cancer-related mortality. Surgical removal of the tumor at an early stage can be curative. However, lung cancer diagnosis at an early stage remains challenging. Th ere is evidence that free fatty acids play a role in cancer development.
Lung cancer is among the most common types of cancer. Surgery is curative only at relatively early stages. By the time lung cancer becomes symptomatic, the best chance for surgical cure is usually well past. Consequently, lethality is high, and lung cancer remains the leading cause of cancer deaths in the United States and worldwide.
Chest radiographs are not sensitive for detection of early-stage lung cancer, and yearly chest radiographs do not reduce lung cancer mortality. 1, 2 Th e only currently accepted method of screening for lung cancer is lowdose CT imaging. 3, 4 However, CT imaging is expensive and exposes patients to small doses of radiation. Furthermore, approximately 95% of lung nodules identifi ed by CT scan are benign, and it can be challenging for radiologists to identify those that are not. 4 Low-dose CT scan screening for lung cancer could, thus, be optimized with tools that improve risk stratifi cation and nodule management.
Fatty acids and phospholipids are necessary for cancer cell proliferation. 5 Platelet activating factor (PAF), a potent phospholipid, promotes lung cancer growth and metastasis. 6 PAF is hydrolyzed by phospholipase A2 to produce lysophospholipid PAFs (lysoPAFs). Patients with lung cancer have increased expression and activity of phospholipase A2. 7, 8 Th is enzyme catalyzes oxidized phospholipids to form lysoPAFs and free fatty acids (FFAs), which, in turn, play a major role in tumor development, angiogenesis, lymphangiogenesis, progression, and metastasis. [9] [10] [11] [12] [13] LysoPAFs show altered expression in cancer cells. Th ey bind to and activate specifi c cell-surface G protein-coupled receptors that initiate cell growth, proliferation, and survival pathways ( Fig 1 ) . 14, 15 LysoPAFs (eg, lysophosphatidylcholines) have been proposed as a potential biomarker for ovarian cancer. 16, 17 Plasma phospholipids, including phosphatidylcholine and lysophosphatidylcholines, may be potential biomarkers in prostate cancer 18 and lung cancer. 19 
Materials and Methods
With Cleveland Clinic Institutional Review Board approval (IRB # 13-306) and informed consent, we retrieved serum samples from 55 patients with lung cancer (cases) from the Cleveland Clinic Lung Biobank. Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Pathologic analysis indicated that 37 had lung adenocarcinoma and 18 had squamous cell carcinoma.
Control subjects were selected from a biobank whose inclusion criteria included age 40 to 75 years and at least one of the following criteria:
(1) current or ex-smoker with at least a 10 pack-year history, (2) a fi rstdegree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD. Specifi c matched control subjects (three for each patient with cancer) were chosen separately for patients with adenocarcinoma and squamous cell carcinoma from among all available control patients (see statistical analysis).
Sample Processing
Samples were centrifuged at 3,000 3 g within 2 h of collection, and the resulting serum was frozen at 2 70°C until assayed. Biochemical analysis was conducted by an investigator who was strictly blinded to cancer status and patient characteristics. Th e theory that elevated FFAs promote cancer is supported by the observation that high dietary linoleic acid (LA) intake promotes breast cancer metastasis in animals. 20, 21 Th e key enzymes for fatty acid synthesis are upregulated in cancer cells, play a critical role in cancer development, and have been chosen as anticancer therapeutic targets. [22] [23] [24] [25] [26] Th e hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadecadienoic acids (HODEs) are stable oxidative products of arachidonic acid (AA) and LA, respectively. Th ere is considerable basic science evidence that FFAs and the oxidized FFAs HETE and HODE promote tumor development, progression, and metastases in lung cancer using cell culture, 27, 28 tissues, [29] [30] [31] and animal models. 27, [32] [33] [34] For example, 5-HETE augments lung cancer cell survival, 30, 35 12-HETE enhances lung cancer cell adhesion, [36] [37] [38] [39] and 15-HETE promotes human lung cancer metastasis 40 and induces angiogenesis. 41, 42 HODE is involved in many types of cancer, although its specifi c role remains unclear. [43] [44] [45] [46] Studies show that 9-HODE and 13-HODE are ligands of peroxisome proliferator-activated receptor-g , which promote lung cancer progression and metastasis. 47, 48 We, therefore, tested the hypotheses that serum concentrations of phospholipids, FFAs, and their metabolites are greater in patients with known lung cancer than in matched patients apparently without cancer.
[ 1 4 6 # 3 C H E S T S E P T E M B E R 2 0 1 4 ]
Two hundred microliters of serum from each patient was used for phospholipid and FFA extraction. To each of the serum samples we added an equal amount of PAF (1-O -hexadecyl-2-acetyl-sn -glycero-3-phosphocholine)-d4 and 15-HETE-d8 (Cayman Chemical Company ) as internal standards for phospholipids or FFAs, respectively. Th e phospholipids and FFAs were extracted first using chloroform/methanol and then further isolated by column chromatography. Fractions of phospholipids and FFA were dried by liquid nitrogen and dissolved in 200 m L of 85% menthol or 50% methanol in high-performance liquid chromatography water, respectively.
Mass spectrometric analyses for phospholipids were performed online using electrospray ionization tandem mass spectrometry in the positive ion mode with multiple reaction monitoring using the molecular 
Results
Propensity matching of the registry patients resulted in well-balanced cancer and control groups for both adenocarcinoma and squamous cell carcinoma, evidenced by nonsignifi cant P values and relatively small standardized diff erences on baseline variables ( Tables 1, 2 ) . 
Statistical Analysis
Specifi c control subjects (three for each patient with cancer) were chosen separately for patients with adenocarcinoma and squamous cell carcinoma from among all available control patients using propensity score matching. For each cancer type, a logistic regression model predicting cancer status (yes or no) from all available baseline variables was constructed, and an estimated propensity score estimated for each patient. Control patients were matched in a 3:1 ratio to the patients with cancer on the propensity score to within 0.2 SDs of the distribution of the logit of the propensity score using a greedy matching algorithm.
Factors included in each propensity score model, regardless of their statistical signifi cance, were sex, age, smoking history (former/never, current), a diagnosis of COPD, a family history of lung cancer, and history of diabetes. For each cancer type, balance on baseline variables between matched patients with cancer and control patients was assessed using the standardized diff erence (ie, the diff erence in means or proportions divided by the pooled SD). For patients with cancer, we also assessed the correlation between stage of cancer and each potential biomarker.
We assessed the diagnostic accuracy of the FFAs and their metabolites for detecting lung cancer using receiver operating characteristic analysis and estimating the area under the curve (AUC) with CI. We searched for best cutpoints for maximizing sensitivity and specifi city with each compound and set a priori that a clinically reliable cutpoint would require observed sensitivity and specifi city of at least 0.70 (arguably, at least 0.90 would be needed before a marker would be used in practice; in this exploratory analysis we purposely set a low bar). For each cancer type we also assessed the univariable and multivariable association between the potential biomarkers and presence of cancer using logistic regression, with results expressed as OR with CIs and overall AUC.
To control the type 1 error at 5% across the assessment of potential biomarkers within each of the two cancer types, we deemed P values significant if P , .05/15 5 .0033, adjusting for six FFAs, seven phospholipids, and the variables LA and AA. With a total of 37 patients with adenocarcinoma and 111 control subjects, we had 90% power at the overall .05 signifi cance level to detect diff erences as small as 0.82 SDs between patients with cancer and control patients on a particular metabolite. With N 5 18 patients with squamous cell carcinoma and 54 control subjects we had 90% power to detect diff erences as small as 1.2 SDs. SAS statistical soft ware (SAS Institute Inc) or the R programming language was used for all analyses. N 5 37 patients with cancer, 111 control subjects. Diagnostic accuracy parameters (sensitivity, specifi city, and so forth) correspond to the given threshold value. CI estimated using bootstrap resampling (percentile method) with 5,000 resamples. Accuracy: ratio of sum of true positives, true negatives, false positives, false negatives to total sample size. Data values represent peak raw biomarker values divided by the corresponding internal standard for each sample. N 5 3 biomarkers met the criteria of having sensitivity and specifi city at the best cutpoint . 
Ratio of Means
In patients with adenocarcinoma, serum oxidized FFAs 5-HETE, 11-HETE, 12-HETE, and 15-HETE ranged an estimated 1.8-to 3.3-fold greater in patients with lung cancer than in patients without cancer ( Fig 2 , Table 3 ) ( P , .001), whereas LA and AA were, respectively, an estimated 1.7 (99.7% CI, 1.2-2.3)-fold and 1.8 (1.4-2.3)-fold greater in patients with cancer than control subjects. No diff erence was found for either 9-HODE ( P 5 .79) or 13-HODE ( P 5 .56). 8-HETE, 9-HETE, and 20-HETE were undetectable in most samples.
Patients with adenocarcinoma had lower concentrations of oxidized phospholipid hydroxyoctadecadienoylphosphatidylcholine (HODE-PC) and 1-O -Hexadecyl-snglycero-3-phosphocholine compared with control subjects without cancer, but no diff erence was found for the other fi ve phospholipids assessed ( P . .0033), including C16-lysoPAF, C18-lysoPAF, and oxidized phospholipid hexadecylazelaoylphosphatidylcholine ( Table 3 ) . For patients with squamous cell carcinoma, none of the FFAs or their metabolites or phospholipids had higher means in patients with cancer vs control patients aft er Bonferroni correction ( Table 4 ) . Tables 5 and 6 report the estimated area under the receiver operating characteristic curve and diagnostic accuracy results for all biomarkers in which the AUC was significantly . 0.50 after Bonferroni correction ( P , .0033). For patients with adenocarcinoma, estimated AUC ranged from 0.71 to 0.82 for metabolites 5-HETE, 11-HETE, 12-HETE, and 15-HETE as well as AA and LA ( Table 5 ). Estimated AUC was 0.47 ( P 5 .59) for 13-HODE and 0.49 ( P 5 .80) for 9-HODE (not shown). In a multivariable logistic regression, AUC increased to 0.87 for patients with adenocarcinoma vs control patients when including any of the biomarkers in Table 5 significant at .05 in the presence of the others (the final backward selection model included 12-HETE, 15-HETE, 9-HODE, and LA). N 5 18 patients with cancer, 54 control subjects. FFA metabolite values are metabolite peak/internal standard peak. Diagnostic accuracy parameters (sensitivity, specifi city, etc.) correspond to the given threshold value. CI estimated using bootstrap resampling (percentile method) with 5,000 resamples. Accuracy: ratio of sum of true positives, true negatives, false positives, false negatives to total sample size. Data values represent peak raw biomarker values divided by the corresponding internal standard for each sample. No biomarkers met the criteria of having sensitivity and specifi city at the best cutpoint .
Diagnostic Accuracy

CI: 99.67%
CIs adjusted for assessing multiple biomarkers using Bonferroni correction; overall a 5 0.05 CI: 99.7% CIs adjusted for assessing multiple biomarkers using Bonferroni correction; overall a 5 0.05. See Table 3 and 5 legends for expansion of abbreviations.
a Jointly maximizes sensitivity and specifi city.
b Estimate using Bayes' theorem assuming a true prevalence of 0.10. AUC P value: testing H0: AUC 5
(1-tailed).
For the adenocarcinoma biomarkers with statistically signifi cant AUC (n 5 8 of 15 tested), estimated sensitivity ranged from 0.65 to 0.73 and estimated specifi city ranged from 0.65 to 0.74 at the thresholds, which maximized sensitivity and specifi city ( Table 5 ). Estimates of accuracy at the chosen thresholds ranged from 0.65 to 0.76. However, only 15-HETE, AA, and LA met our a priori "usefulness" criterion of having both observed sensitivity and observed specifi city . 0.70 at the chosen threshold. Figure 3 plots the receiver operating characteristic curve of sensitivity vs 1 minus specifi city at each observed value for these three candidate biomarkers.
In patients with squamous cell carcinoma, the AUC was signifi cantly . 0.50 in the four biomarkers/phospholipids shown in Table 6 : AA, LA, 11-HETE, and lysoPAF. Of those, estimated sensitivity and specifi city was . 0.70 only for lysoPAF.
Discussion
Serum concentrations of FFAs and their oxidized metabolites (HETEs and HODEs) were substantially greater in patients with lung adenocarcinoma than in similar patients without cancer. Among the potential biomarkers we evaluated, AA, LA, and 15-HETE showed the best combination of sensitivity and specifi city ( . 0.70) and AUC (range, 0.76-0.82).
Predictive value for adenocarcinoma was improved by considering combinations of FFAs and metabolites in a multivariable model, with a combined AUC of 0.87. Th ese results suggest that these serum molecules, or a combination of them, may be good biomarkers for lung adenocarcinoma diagnosis.
In contrast to adenocarcinoma, in patients with squamous cell cancer, only C18-lysoPAF passed our criterion of signifi cant AUC and observed sensitivity/specifi city . 53 Stability of these molecules makes them clinically practical biomarkers, because special specimen handling is unnecessary.
Th ese patients with lung cancer and control patients were matched on age, sex, smoking status, family history of lung cancer, and history of diseases such as diabetes and COPD. Furthermore, both groups were selected from a similar population seen in the Cleveland Clinic Pulmonary Clinic. Although it remains probable that the cancer and control populations diff ered on some unknown but important factors, the very substantial diff erences in the FFA-based biomarker concentrations is most likely to result from the metabolic changes associated with the presence of lung cancer. Lung cancer was the only tumor we evaluated; whether FFA, HETE, and HODE are comparably elevated in patients with other types of cancer remains unknown.
The current report reflects the results of a discoverylevel project. Much additional work is required to Table 5 ). See Figure 2 legend for expansion of abbreviations.
determine the potential clinical usefulness of an FFAbased lung cancer serum biomarker. Our testing set included all stages of lung cancer. To develop the biomarker for early identification will require validation of the results within an independent cohort with a focus on early-stage lung cancers. Characterizing true and false results will help to determine its potential clinical application. The testing platform used must be translated into a laboratory-ready platform and validated to deliver accurate results consistently. Potential applications of a validated FFA-based lung cancer serum biomarker that might be explored include identification of high-risk patients for enrollment in lung cancer screening programs, characterization of lung nodules, monitoring the response to therapy, and characterizing the nature of an individual's cancer.
In summary, serum FFAs and their oxidized metabolites, HETE and HODE, were elevated in patients with lung adenocarcinoma. Among these, AA and LA and 15-HETE were best able to distinguish cancer from noncancer status measured by the AUC and also had the best sensitivity and specifi city. Future work could identify a role for these compounds in the identifi cation and characterization of lung cancer. Financial/nonfi nancial disclosures: Th e authors have reported to CHEST the following confl icts of interest: Drs Liu and Sessler have intellectual property related to this report. Dr Mazzone has intellectual property related to other methods of detecting lung cancer. Drs Cata, Kurz, Bauer, and Mascha have reported that no potential confl icts of interest exist with any companies/organizations whose products or services may be discussed in this article .
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